Abbott Laboratories vs Stryker
Abbott Laboratories is the larger business, with $44.33bn of revenue in fiscal 2025 against $25.12bn for Stryker (1.8 times as much). Stryker grew faster (11.2% against 5.7%). Abbott Laboratories kept more of each dollar of sales as profit: a net margin of 14.7% against 12.9%. Abbott Laboratories carries less debt relative to equity (24.8% against 70.7%).
| Latest fiscal year | Abbott LaboratoriesABT, 2025 | StrykerSYK, 2025 |
|---|---|---|
| Revenue | $44.33bn | $25.12bn |
| Revenue growth | 5.7% | 11.2% |
| Net income | $6.52bn | $3.25bn |
| Operating margin | 18.2% | 19.5% |
| Net margin | 14.7% | 12.9% |
| Return on equity | 13.1% | 15.1% |
| Free cash flow | $7.39bn | $4.28bn |
| Cash | $8.52bn | $4.01bn |
| Total debt | $12.93bn | $15.86bn |
| Debt to equity | 24.8% | 70.7% |
| Dividend per share | $2.40 | — |
| Dividend yield | 2.2% | 1.1% |
| Share buybacks | $893m | — |
| Employees | 115,000 | 56,000 |
| Market value | $190.32bn | $118.94bn |
| Price vs our value range | Above our value range | Within our value range |
| Moat score | 72 (Strong) | 78 (Strong) |
| Insider trades, 12 months | 6 buys, 11 sales | 0 buys, 71 sales |